Business Insider is reporting that as news that Donald Trump will be the 45th president sent stocks into an early Thursday tumble in Europe, by around 9:50 a.m. in London (4:50 a.m. EST), pharmaceutical stocks were rising, with Hikma Pharmaceuticals’s stock up 6% on the FTSE 100. Roche and Novartis saw stock increases over 4% and GSK saw a 1.8% bump. Jefferies pointed to hope that efforts to enact new pricing rules on drugs led the swell, telling Business Insider, “Sentiment towards the Healthcare sector ought to swing initially away from draconian fears over drug pricing.” (Business Insider)
Endo has announced the appointment of two key executive leadership team members, naming Terrance J. Coughlin its EVP and COO, and adding Tony Pera as the president of Endo’s U.S. generics company Par Pharmaceutical.
The company will collaborate with Bluepharma to develop and distribute a generic product in a category with U.S. sales more than $75 million, according to QuintilesIMS data for the 12 months ended July 2016.